
CLINICAL TRIALS
and
TRANSLATIONAL RESEARCH
Rare Disease Discovery: B3 for NMD - Bench to Bedside and Back- Transformative discoveries leading to improved care in Neuromuscular Disease
Status: Ongoing, Open for Recruitment
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 24-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects with Facioscapulohumeral Muscular Dystrophy (FSHD)
Status: Ongoing, Recruitment closed
A Phase II Randomized, Placebo-Controlled, Double-Blinded, Multi-Centre Clinical Trial of Pimozide in Patients with Amyotrophic Lateral Sclerosis
Status: Ongoing, Open for Recruitment
A Phase 2a, Multicentre, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients
Status: Ongoing, Open for Recruitment
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 24-Week, Phase 2a Study of Topical Pirenzepine (WST-057) or Placebo in Type 2 Diabetic Patients with Peripheral Neuropathy
Status: Ongoing, Open for Recruitment
A Pilot, Open-label, Dose-response Study Investigating the Effect of Low-dose Celecoxib on SMN2 in Patients with Spinal Muscular Atrophy CEL20150
Status: TBA
Enhanced CARE for RARE Genetic Diseases in Canada (C4R)
Status: Open for Recruitment
Factors Influencing Pursuit of Medical Assistance in Dying (MAID) in ALS Patients
Status: Ongoing, Open for Recruitment
Understanding Palliative Care and End of Life Needs in the ALS Population: The First Step to Improving Patient and Caregiver Quality of Life
Status: Ongoing, Open for Recruitment
A Prospective, Multi-center, Observational Study of the Safety, Tolerability, and Effectiveness of SPINRAZA in Adult Patients with Spinal Muscular Atrophy
Status: Ongoing, Open for Recruitment
To participate in our clinical trials, please contact Maria Duff (maduff@ohri.ca) or Sergio Guber (sguber@ohri.ca).